Premium
Quantification of angiongenesis as an independent predictor of prognosis in invasive bladder carcinomas
Author(s) -
DICKINSON A. J.,
FOX S. B.,
PERSAD R. A.,
HOLLYER J.,
SIBLEY G. N. A.,
HARRIS A. L.
Publication year - 1994
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1994.tb07122.x
Subject(s) - medicine , cd31 , stage (stratigraphy) , univariate analysis , pathology , microvessel , proportional hazards model , angiogenesis , oncology , hazard ratio , urology , multivariate analysis , biology , confidence interval , paleontology
Objective To evaluate angiogenesis as a prognositic marker of transitional cell carcinoma of the bladder and to assess its relationship to established variables for survival. Materials and methods Forty‐five tumours (two G 2 T 2 , seven G 3 T 2 and 36 G 3 T 3 ) from 36 men and nine women with a mean age of 73 years (range 50–91), who has been fokllowed‐up for a median of 37 months (range 1–50), were examined, Wessels w ere immunohistochemically highlighted using an antibody to the platelet endothelial cell adhesion molecule, CD31. Microvessel density was quantified using a Chalkley point eyepiece graticule. Results Univariate analysis of survival showed stage, grade and vascular count were significant inducatiors of prognosis (P=0.002. P=0.007, P=0.019 respectively). No relationship was observed between stage and grade and vascular count. In a Cox proportional hazard model, adjiusted for age and stage, microvessel d ensity not only remained a significant prognositc indicator (P=0.026) but was as informative as stage in predicting overall survival. A high vascular count conferred a 2.5 increased risk of mortality. Conclusions These findings suggest that assessment of anigogenesis by microvessel quantification is an independent predictor of survival in patients with invasive bladder carcinoma and might be useful in selecting those who would benefit from adjuvant therapy.